Variable

Placebo (n = 35)

ALA 300 mg (n = 40)

Vitamin E 700 IU (n = 40)

ALA 300 mg plus vitamin E 700 IU (n = 40)

HOMA score Baseline Posttreatment Change from baseline

4.2 3.9 −7.1%

4.6 2.1 −54.3%

4.1 1.9 −53.7%

4.6 1.1 −76.1%

Triglycerides, mg/dL Baseline Posttreatment Change from baseline

276 239 −13.4%

285 187 −34.4%

280 175 −37.5%

298 130 −56.4%

RBP-4, µg/mL Baseline Posttreatment Change from baseline

3.5 3.1 −11.4%

3.9 2.1 −46.2%

4.3 2.3 −46.5%

4.2 1.6 −61.9%

Leptin, ng/mL Baseline Posttreatment Change from baseline

34 22 −35.3%

29 16 −44.8%

32 17 −46.9%

29 12 −58.6%

Adiponectin, µg/mL Baseline Posttreatment Change from baseline

1.2 1.8 50%

0.9 2.0 122.2%

1.2 2.3 91.7%

0.9 1.9 111.1%

Hemoglobin A_1c, % Baseline Posttreatment Change from baseline

6.1 5.9 −3.3%

6.6 5.7 −13.6%

6.8 5.3 −22%

6.2 5.1 −17.7%

ALT, U/L Baseline Posttreatment Change from baseline

46 32 −30.4%

48 38 −20.8%

54 32 −40.7%

58 32 −44.8%

Fibrosis score Baseline Posttreatment Change from baseline

0.15 0.15 0%

0.17 0.16 −5.9%

0.15 0.16 6.7%

0.18 0.17 −5.6%